Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.75 |
| ▸ | RAB9A | P51151 | 10/20 | 0.75 |
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.63 |
| ▸ | ITK | Q08881 | 3/20 | 0.61 |
| ▸ | SCD | O00767 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28527319 | 0.87 | CNR1 (0.64) | NPC1RAB9ACNR1SMN1; SMN2CYP1A2 | |
| SCHEMBL30944323 | 0.87 | CNR1 (0.64) | NPC1RAB9ACNR1SMN1; SMN2CYP1A2 | |
| SCHEMBL30944425 | 0.86 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL30944320 | 0.86 | DYRK1A (0.64) | NPC1RAB9ACNR1SMN1; SMN2CYP1A2 | |
| SCHEMBL4919716 | 0.85 | EPHX2 (0.67) | NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL13778842 | 0.84 | CNR1 (0.72) | NPC1RAB9ACNR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30944353 | 0.83 | CNR1 (0.70) | NPC1RAB9ACNR1SMN1; SMN2CYP2C19 | |
| SCHEMBL28529053 | 0.83 | CNR1 (0.70) | NPC1RAB9ACNR1SMN1; SMN2CYP2C19 | |
| SCHEMBL28530232 | 0.82 | NPC1 (0.59) | NPC1RAB9ACNR1SMN1; SMN2CYP1A2 | |
| SCHEMBL963747 | 0.81 | CLK1 (0.76) | NPC1RAB9ACNR1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | NPC1 1713/4885RAB9A 3792/4885CNR1 4097/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | NPC1 3462/4885RAB9A 3771/4885CNR1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.